U.S. Department of Health & Human Services
National Institutes of Health
NCATS
This repository is under review for potential modification in compliance with Administration directives.
Dismiss
Return Home
Inxight
Drugs
Search Substances
Home
Browse Drugs
US Approved Drugs
Marketed Drugs
Investigational Drugs
All Substances
Search
Structure Search
Sequence Search
Downloads
About
Search Substances
XMAB-2513
33VWC847G8
Investigational
General
Record Details
Names
3
Classification
3
Identifiers
2
Concept Definition
Relationships
1
Active Moiety
1
XMAB-2513
33VWC847G8
Investigational
General
Approval Year
Unknown
149,124
Record Details
Substance Class
Concept
Record UNII
33VWC847G8
Record Status
Validated (UNII)
Record Version
10
9
8
7
6
5
4
3
2
1
Names
3
Show
5
20
100
All
entries
Name
Type
Language
Name
Type
Language
XMAB-2513
Code
English
XMAB2513
Preferred Name
English
ANTI-CD30 MONOCLONAL ANTIBODY XMAB2513
Common Name
English
Showing 1 to 3 of 3 entries
Previous
1
Next
Classification
3
Show
5
20
100
All
entries
Classification Tree
Code System
Code
Classification Tree
Code System
Code
Biological Agent
Pharmacologic Substance
[C1909]
Biological Agent
[C307]
Monoclonal Antibody
NCI_THESAURUS
C20401
Designated
ORPHAN DRUG
Designated
Treatment of Hodgkin lymphoma
FDA ORPHAN DRUG
271208
Antineoplastic Biological Agent
Pharmacologic Substance
[C1909]
Biological Agent
[C307]
Antineoplastic Biological Agent
[C129821]
Antineoplastic Antibody
NCI_THESAURUS
C129822
Showing 1 to 3 of 3 entries
Previous
1
Next
Identifiers
2
Show
5
20
100
All
entries
Code System
Code
Type
Description
Code System
Code
Type
Description
NCI_THESAURUS
C74005
PRIMARY
NCIT
FDA UNII
33VWC847G8
PRIMARY
Showing 1 to 2 of 2 entries
Previous
1
Next
Concept Definition
This is a non-substance concept
Relationships
1
Show
5
20
100
All
entries
Related Record
Type
Details
Related Record
Type
Details
4K108E14CS
TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBER 8
TARGET->LIGAND
Comments:
Anti-CD30 monoclonal antibody XmAb2513 specifically binds to the CD30 antigen, which may result in a cytotoxic T lymphocyte (CTL) response against CD30-expressing tumor cells.
Showing 1 to 1 of 1 entries
Previous
1
Next
Active Moiety
1
Show
5
20
100
All
entries
Related Record
Type
Details
Related Record
Type
Details
33VWC847G8
XMAB-2513
ACTIVE MOIETY
Showing 1 to 1 of 1 entries
Previous
1
Next
This is a non-substance concept
